China News Service, Guangzhou, August 13 (Cai Minjie, Lin Zhiwei) Lung cancer ranks first in tumor morbidity and mortality worldwide, and most patients have advanced disease at the time of diagnosis
Non-small cell lung cancer accounts for about 85% of all lung cancer cases, and it is often found at an advanced stage
In Asian populations, 50% of non-small cell lung cancer patients will have epidermal growth factor receptor (EGFR) gene mutations.
Erlotinib is an oral antitumor drug that inhibits the growth of tumor tissue by inhibiting the activity of epidermal growth factor receptor tyrosine kinase and blocking downstream signal transduction
Lung cancer has gradually entered the era of chronic disease, and the concept of precision treatment has been deeply rooted in the hearts of the people
According to Zhou Qing, deputy director of the Guangdong Lung Cancer Research Institute, in 2015, a phase III study for the first-line treatment of EGFR-mutant advanced non-small cell lung cancer patients in China was carried out by Wu Yilong’s team and 14 centers in China.
The above-mentioned research team believes that bevacizumab is a recombinant humanized anti-vascular endothelial growth factor monoclonal immunoglobulin G1 antibody, which can inhibit tumor angiogenesis and ultimately achieve the goal of "starving" the tumor
globulin The above study included 311 patients with untreated EGFR-mutant advanced non-small cell lung cancer.
As of January 18, 2019, the study found that compared with 11.
The study also found that the toxicity of the combination therapy is manageable and tolerable, and no new safety signals have been found
This study confirmed that bevacizumab combined with erlotinib has clinical benefits and controllable safety risks in the treatment of Chinese patients with advanced non-small cell lung cancer with EGFR-sensitive mutations
Zhong Wenzhao, director of the Guangdong Institute of Lung Cancer, found that the combined treatment of erlotinib and bevacizumab not only significantly prolonged the progression-free survival of the overall population, but even has a trend of prolonging the overall survival in patients with brain metastases
Wu Yilong, the honorary director of Guangdong Lung Cancer Research Institute, said that lung cancer is a serious life-threatening disease.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
